Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHACRYNATE SODIUM vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.
Treatment of edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema,Off-label: Adjunct in treatment of acute hypercalcemia
Moderate to severe pain relief; combinations are used to reduce abuse potential.
50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.
Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease.
Pentazocine has an elimination half-life of 2-3 hours in healthy adults, which may be prolonged in patients with hepatic impairment. Naloxone has a terminal half-life of 0.5-1.5 hours in adults, with a rapid decline in plasma levels; the short half-life limits its duration of opioid antagonism.
Primarily metabolized by hepatic glutathione S-transferase (GST) to a cysteine conjugate; minor metabolism via oxidation. Excreted in urine and bile.
Pentazocine is metabolized primarily by hepatic conjugation (glucuronidation) and oxidation via CYP2C19 and CYP2D6; naloxone is extensively metabolized by the liver, primarily via glucuronidation (UGT2B7).
Renal: approximately 30% unchanged; biliary/fecal: minor (less than 10%); majority metabolized to cysteine adducts excreted in urine.
Pentazocine is primarily metabolized in the liver and excreted in urine as conjugates of glucuronide and sulfate, with about 60% of a dose excreted renally within 24 hours as metabolites and unchanged drug (less than 5% unchanged). Naloxone undergoes extensive hepatic metabolism to naloxone-3-glucuronide, which is excreted renally; approximately 50% of a dose is excreted as conjugates in urine within 6 hours.
Approximately 95% bound, primarily to albumin.
Pentazocine: Approximately 35-65% bound to plasma proteins (mainly albumin). Naloxone: Approximately 32-45% bound to plasma proteins (mainly albumin).
0.1-0.2 L/kg (small Vd, consistent with high protein binding and limited extravascular distribution).
Pentazocine: Vd ~2-3 L/kg, indicating extensive tissue distribution. Naloxone: Vd ~2-3 L/kg, also indicating wide distribution.
Oral: approximately 100% (well absorbed, no significant first-pass metabolism).
Oral pentazocine: 20-30% due to first-pass metabolism. Intramuscular pentazocine: 100%. Subcutaneous pentazocine: 100%. Oral naloxone: <2% due to extensive first-pass metabolism. Intramuscular and subcutaneous naloxone: 100%. Intravenous: 100% for both.
e GFR 30-59 m L/min: reduce dose by 50%; e GFR <30 m L/min: avoid use or use with extreme caution.
GFR 30-50 m L/min: Administer every 6 hours; GFR 10-29 m L/min: Administer every 8-12 hours; GFR <10 m L/min: Administer every 12 hours or consider alternative.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% or extend interval; Child-Pugh Class C: Avoid use.
1 mg/kg intravenously once daily; maximum 50 mg/day. Not recommended in neonates.
Not recommended for children under 12 years. For older children (≥12 years): Pentazocine 50 mg (with naloxone 0.5 mg) orally every 3-4 hours as needed; maximum 6 tablets daily.
Start at 25 mg intravenously once daily; increase slowly due to increased risk of electrolyte disturbances and hypotension.
Initiate with half the usual adult dose (one-half tablet) and titrate carefully due to increased sensitivity and risk of respiratory depression.
Ethacrynic acid (ethacrynate) can cause profound diuresis with water and electrolyte depletion; close medical supervision and dose titration are required.
Risk of respiratory depression, particularly in elderly, cachectic, or debilitated patients; risk of addiction, abuse, and misuse; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of life-threatening respiratory depression when used with benzodiazepines or other CNS depressants.
May cause severe electrolyte disturbances (hypokalemia, hyponatremia, hypochloremia) and volume depletion,Ototoxicity, especially with rapid IV administration or in patients with renal impairment; may be irreversible,Hyperuricemia and gout,Hepatic coma can be precipitated in patients with cirrhosis or ascites,May increase risk of digoxin toxicity due to hypokalemia,Photosensitivity reaction possible
Respiratory depression; hypotension; increased intracranial pressure; seizure risk (pentazocine); opioid-induced hyperalgesia; adrenal insufficiency; severe hypotension; interaction with MAOIs; risk of dependence and withdrawal; gastrointestinal obstruction; impaired renal or hepatic function; head injury.
Anuria,Hypersensitivity to ethacrynic acid or any component,Severe electrolyte depletion (hypokalemia, hyponatremia, hypochloremia),Hepatic coma or precoma
Hypersensitivity to pentazocine or naloxone; significant respiratory depression; acute or severe bronchial asthma; GI obstruction; known or suspected paralytic ileus; patients receiving MAOIs or within 14 days.
Avoid excessive intake of salt substitutes containing potassium unless advised by your doctor. Grapefruit juice may enhance diuretic effect; monitor for hypotension. Alcohol can increase diuretic effect and risk of hypotension. Caffeine may worsen electrolyte imbalance. Ensure adequate fluid intake unless fluid restriction is prescribed.
No specific food interactions are reported for this combination. However, grapefruit juice may theoretically affect metabolism via CYP3A4 (pentazocine is metabolized by CYP3A4), but clinical significance is unknown. Advise patients to maintain a consistent diet.
Ethacrynate sodium crosses the placenta. First trimester: Limited human data; animal studies not available. Second and third trimesters: Potential for electrolyte disturbances, ototoxicity, and oligohydramnios in the fetus due to diuretic effect. Avoid use in pregnancy unless clearly needed.
Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Third trimester: Chronic use may cause fetal dependence; neonatal withdrawal syndrome reported. High doses near term may cause neonatal respiratory depression.
Excreted into breast milk in low concentrations; M/P ratio not determined. Potential for adverse effects in nursing infants (e.g., electrolyte imbalance, diuresis). Weigh benefits against risks; consider alternative diuretics.
Pentazocine is excreted in breast milk in small amounts (estimated relative infant dose <3%). Naloxone is poorly bioavailable orally. Generally considered compatible with breastfeeding; monitor infant for sedation or poor feeding. M/P ratio for pentazocine is approximately 1.0.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, specific dose adjustments for ethacrynate sodium are not established. Use lowest effective dose and monitor for hypotension and electrolyte imbalances.
No established dose adjustments for pregnancy; however, pharmacokinetic changes (increased volume of distribution, enhanced clearance) may require higher or more frequent doses of pentazocine for adequate analgesia. Use lowest effective dose and shortest duration.
Ethacrynate sodium is a loop diuretic used for patients with sulfonamide allergy as it is not a sulfonamide derivative. Monitor for ototoxicity, especially in patients with renal impairment or when used with other ototoxic drugs. Rapid IV administration can cause severe hypotension; infuse slowly over several minutes. Hypokalemia and hypomagnesemia are common; monitor electrolytes and consider potassium-sparing diuretic or supplementation. Ethacrynic acid can cause GI bleeding; use with caution in peptic ulcer disease.
Naloxone in this fixed-dose combination is included to deter opioid abuse by reversing euphoria. The pentazocine component is a mixed agonist-antagonist opioid; naloxone has poor oral bioavailability but becomes active parenterally, precipitating withdrawal in opioid-dependent individuals. Use with caution in patients with impaired renal or hepatic function. Monitor for respiratory depression, especially in opioid-naive patients, as pentazocine alone can cause respiratory depression.
Take this medication exactly as prescribed, usually once or twice daily.,You may need to urinate frequently; take your last dose of the day early to avoid nighttime urination.,Avoid alcohol and limit salt intake to help reduce fluid retention.,Report any hearing loss, ringing in the ears, or dizziness to your healthcare provider immediately.,Eat potassium-rich foods like bananas, oranges, or potatoes unless directed otherwise by your doctor.,Weigh yourself daily and report sudden weight gain or loss to your healthcare provider.,Do not take any over-the-counter medications, especially NSAIDs, without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose.
Take exactly as prescribed; do not crush or inject tablets, as injected naloxone can cause severe withdrawal in opioid-dependent individuals.,This medication contains naloxone to discourage misuse; injection will cause withdrawal symptoms.,Report any signs of withdrawal (e.g., nausea, vomiting, sweating, agitation) or breathing difficulty.,Avoid alcohol and other central nervous system depressants as they increase risk of respiratory depression.,Do not use with other opioids unless directed, as effects are unpredictable.,Keep out of reach of children; accidental ingestion may cause severe respiratory depression.
No interactions on record
"Cobicistat is a potent CYP3A4 inhibitor used to boost the pharmacokinetics of antiretroviral agents like atazanavir and darunavir. Naloxone primarily undergoes glucuronidation via UGT1A6 and UGT2B7, with minor CYP3A4 metabolism. Concomitant use with Cobicistat may modestly increase naloxone exposure due to CYP3A4 inhibition, but this is unlikely to be clinically significant given naloxone's wide therapeutic index and short half-life."
"Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), is primarily metabolized by cytochrome P450 (CYP) 1A2 and 2D6. Naloxone, an opioid antagonist, is reported to inhibit CYP1A2, potentially decreasing the clearance of fluvoxamine. This interaction may lead to increased fluvoxamine plasma concentrations, elevating the risk of serotonin syndrome, QT prolongation, and other dose-dependent adverse effects, especially in patients receiving high doses or those with hepatic impairment."
"Naloxone, an opioid receptor antagonist, may inhibit the cytochrome P450 isoenzyme CYP3A4, which is responsible for the metabolism of ivacaftor. Concomitant administration can lead to reduced clearance of ivacaftor, resulting in elevated serum concentrations. This increase may potentiate the therapeutic effects and adverse reactions of ivacaftor, such as hepatotoxicity and QT prolongation."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHACRYNATE SODIUM vs NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE, answered by our medical review team.
ETHACRYNATE SODIUM is a Loop Diuretic that works by Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is a Opioid Agonist-Antagonist that works by Pentazocine is a mixed agonist-antagonist opioid that binds to mu-opioid receptors (partial agonist) and kappa-opioid receptors (agonist), producing analgesia. Naloxone is a pure opioid antagonist that competitively blocks mu, kappa, and delta receptors; when administered orally, naloxone undergoes extensive first-pass metabolism, reducing systemic absorption and primarily blocking the effects of pentazocine if the combination is misused parenterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHACRYNATE SODIUM and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHACRYNATE SODIUM is: 50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.. The standard adult dose of NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is: Oral: One tablet (naloxone 0.5 mg / pentazocine 50 mg) every 3-4 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHACRYNATE SODIUM and NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHACRYNATE SODIUM is classified as Category C. Ethacrynate sodium crosses the placenta. First trimester: Limited human data; animal studies not available. Second and third trimesters: Potential for electrolyte disturbances, oto. NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE is classified as Category A/B. Pentazocine crosses the placenta; naloxone has limited placental transfer. No well-controlled human studies. First trimester: Risk cannot be excluded; avoid if possible. Second/Thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.